Event News

Navigating Regulatory Pathways for Pharmabiotics

The PRI, as a neutral and financially independent non-profit association, has developed and applied its Regulatory Strategy since 2013 – Scientific Advice Request dossiers, European regulatory research & intelligence, and Task Group initiatives to provide regulatory insight for its members. Today, the PRI has been identified by European regulatory authorities as a key representative body in the European microbiome/ health ...
Read More

Immuno-Oncology & the Microbiome

The microbiome is receiving significant attention in regards to its influence on cancer. Its role in response to cancer treatment is becoming increasingly evident, with research showing that harnessing the gut microbiome may affect responses to numerous forms of cancer treatments. Several companies are now looking to develop microbiome-based complementing therapeutics as well as LBPs designed to potentially treat tumours ...
Read More

Microbiome-Based Therapeutics for the Skin

Microbiome-Based Therapeutics for Skin The skin is the human body’s largest organ, colonized by a diverse milieu of microorganisms, including both aerobic bacteria (staphylococci and streptococci) and anaerobic bacteria (propionibacteria), which are directly involved in several severe skin diseases such as psoriasis, atopic dermatitis and acne. This session explores methods of understanding the skin microbiome, treating skin diseases with live and/or ...
Read More

Key Note Presentations

Day 1 & Day 2 Key Note Presentations. Translating the Microbiome in the Era of Personalised Medicine By Joesph Petrosino, Interim-Chairman, Department of Molecular Virology and Microbiology, Baylor College of Medicine. The Alkek Center for Metagenomics and Microbiome Research (CMMR) at Baylor College of Medicine is pursuing numerous research and development efforts in the study of how the microbiome impacts ...
Read More

Understanding, Leveraging & Engineering the Human Virome

The human virome is the total collection of viruses in and on the human body. Viruses in the human body may infect both human cells and other microbes such as bacteria (as with bacteriophages). This session will look at understanding these viral communities, the potential for leveraging viruses to treat disease, regulatory and manufacturing challenges as well as synthetically programming bacteriophages ...
Read More

Development Process Technologies: From Bench to Bedside

Maximising Efficiency in the LBP Development Process  From new ways of understanding mechanisms of action, to alternative bacterial enumeration techniques, through to documentation and validation - What are the future methods and technologies likely to be adopted to help maximise speed to market efficiency when taking Microbiotic Medicinal Products from bench to bedside? Below is a preview of the latest developments that will ...
Read More

Pharmabiotics 2019 Young Investigator Awards

Pharmabiotics 2019 Young Investigator Awards Co-initiated by the Pharmabiotic Research Institute (PRI) and Institut Mérieux through its affiliate Biofortis Mérieux NutriSciences, an award of €10,000 is allocated to a young clinician or academic, working within the field of Microbiotic Medicinal Products. An independent expert committee is selected from the PRI’s extensive network of human microbiota thought leaders to review the ...
Read More

2019 Conference Committee and Sessions

The Pharmabiotics 2019 Scientific Committee (left to right): Bruno Pot, President, Pharmabiotic Research Institute Adrien Nivoliez, CEO, Biose Industrie Magali Cordaillat-Simmons, Scientific & Regulatory Affairs Director, Pharmabiotic Research Institute Marco Pane, R&D Director, Probiotical Travis Whitfill, Chief Scientific Officer, Azitra Inc Ashton Harper, Medical Affairs Director, Protexin Sarah Lebeer, Associate Professor, University of Antwerp Lindsay Hall, Quadrum Institute With the ...
Read More